Literature DB >> 2121695

Suppression by interleukin 4 of activation of human blood monocytes to the tumoricidal state.

Y Nishioka1, S Sone, A Okubo, T Ogura.   

Abstract

The effect of interleukin 4 (IL-4) on expression of antitumor activity of blood monocytes purified by counter-flow centrifugal elutriation from healthy donors was examined. The blood monocytes were incubated for 24 h in medium with lipopolysaccharide, interferon gamma (IFN-gamma) or desmethyl muramyl dipeptide (norMDP) or with IFN-gamma and norMDP in the presence of IL-4, and then their tumoricidal activity was assayed by measuring 125IUdR release from human melanoma (A375) cells. Irrespective of activation stimulus, addition of IL-4 to cultures of monocytes and activators resulted in dose-dependent suppression of the tumoricidal activity of monocytes against parent A375 melanoma cells and the variant cells, A375-R resistant to IL-1 and tumor necrosis factor alpha. IL-4 suppressed the early induction phase of monocyte activation. Rabbit anti-IL-4 antisera completely blocked the IL-4-mediated suppression of monocyte activation to the tumoricidal state. These findings suggest that IL-4 is important in vivo in down-regulation of anti-tumor expression of monocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121695      PMCID: PMC5918117          DOI: 10.1111/j.1349-7006.1990.tb02670.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


fetal bovine serum interferon γ interleukin 4 lipopolysaccharide desmethyl muramyl dipeptide tumor necrosis factor α
  29 in total

1.  Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.

Authors:  T Utsugi; S Sone
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

2.  IL-4 down-regulates IL-1 and TNF gene expression in human monocytes.

Authors:  R Essner; K Rhoades; W H McBride; D L Morton; J S Economou
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

3.  Interleukin-4 induces secretion of CSF for granulocytes and CSF for macrophages by peripheral blood monocytes.

Authors:  M Wieser; R Bonifer; W Oster; A Lindemann; R Mertelsmann; F Herrmann
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

Review 4.  Secretory products of macrophages.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  Human T cells and interleukin 4 inhibit the release of interleukin 1 induced by lipopolysaccharide in serum-free cultures of autologous monocytes.

Authors:  L Weiss; N Haeffner-Cavaillon; M Laude; J M Cavaillon; M D Kazatchkine
Journal:  Eur J Immunol       Date:  1989-07       Impact factor: 5.532

6.  Evidence for effects of interleukin 4 (B cell stimulatory factor 1) on macrophages: enhancement of antigen presenting ability of bone marrow-derived macrophages.

Authors:  A Zlotnik; M Fischer; N Roehm; D Zipori
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

7.  Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells.

Authors:  C Bucana; L C Hoyer; B Hobbs; S Breesman; M McDaniel; M G Hanna
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

8.  Normal human alveolar macrophages have more ability than blood monocytes to produce cell-associated interleukin-1-alpha.

Authors:  S Sone; A Okubo; T Ogura
Journal:  Am J Respir Cell Mol Biol       Date:  1989-12       Impact factor: 6.914

9.  IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.

Authors:  Y Kawakami; M C Custer; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

10.  Inhibition of human macrophage colony formation by interleukin 4.

Authors:  J H Jansen; G J Wientjens; W E Fibbe; R Willemze; H C Kluin-Nelemans
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.